Literature DB >> 16336439

Fatty liver and the metabolic syndrome among Shanghai adults.

Jian-Gao Fan1, June Zhu, Xing-Jian Li, Lan Chen, Yuan-San Lu, Lui Li, Fei Dai, Feng Li, Shi-Yao Chen.   

Abstract

BACKGROUND AND AIM: To explore the relationship between fatty liver and the metabolic syndrome in the adults of Shanghai and evaluate the value of fatty liver as a marker for risk factor clustering.
METHODS: Questionnaires, physical examinations, laboratory tests (blood lipid and glucose) and real-time liver ultrasonographies were performed in Shanghai adults and analyzed using randomized, multistage, stratified cluster sampling. Prevalence of the metabolic syndrome was defined by the National Cholesterol Education Program-Adult Treatment Panel III (NCEP-ATPIII) criteria with the exception of abdominal obesity (waist circumference > 90 cm in men and > 80 cm in women); fatty liver was diagnosed in accordance with the presence of an ultrasonographic pattern consistent with 'bright' liver (brightness and posterior attenuation of liver).
RESULTS: The study population consisted of 3175 subjects (1218 men) with a mean (+/- SD) age of 52.4 +/- 15.1 years. Metabolic syndrome and fatty liver were found in 726 (22.87%) and 661 (20.82%) of sampled cases, respectively. After adjustment by age and sex, the prevalence of the metabolic syndrome and fatty liver in the general population of Shanghai were 15.30 and 17.29%, respectively. The risk for fatty liver in subjects with abdominal obesity, diabetes, dyslipidemia and hypertension increased 32.78-fold (95% confidence interval (CI) 14.85-72.35), 31.58-fold (95% CI 14.18-70.35), 22.64-fold (95% CI 10.26-49.99) and 23.25-fold (95% CI 10.54-51.30), respectively, compared with controls, whereas the risk for fatty liver in subjects with metabolic syndrome was increased by 39.33-fold (95% CI 17.77-87.05). After the 661 patients with fatty liver had been stratified by body mass index (BMI), the prevalence of abdominal obesity, hypertension and the metabolic syndrome were increased from 25.0, 47.2 and 36.1%, respectively, in people with normal BMI to 81.0, 73.8 and 55.4%, respectively, in obese persons. However, the prevalence of hypertriglyceridemia, high fasting glucose and low high-density lipoprotein-cholesterol showed no significant changes with increased BMI. Moreover, among fatty liver patients with normal BMI, the detection rate for one or more features of metabolic disorders was as high as 83.3% and that for five features was 2.8%. Compared with obesity (BMI > or = 25 kg/m2) and abdominal obesity, fatty liver had the highest clustering rate, specificity, positive predictive value and attributable risk percentage in detecting risk factor clustering in both sexes.
CONCLUSIONS: There is a high prevalence of metabolic syndrome and fatty liver among Shanghai adults. Metabolic disorders are closely related to fatty liver; moreover, fatty liver appears to be a good predictor for the clustering of risk factors for metabolic syndrome.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16336439     DOI: 10.1111/j.1440-1746.2005.04058.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  60 in total

1.  PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease.

Authors:  Elizabeth K Speliotes; Johannah L Butler; Cameron D Palmer; Benjamin F Voight; Joel N Hirschhorn
Journal:  Hepatology       Date:  2010-09       Impact factor: 17.425

2.  Treatment options for nonalcoholic fatty liver disease.

Authors:  Brian Lam; Zobair M Younossi
Journal:  Therap Adv Gastroenterol       Date:  2010-03       Impact factor: 4.409

3.  Fatty liver is associated with dyslipidemia and dysglycemia independent of visceral fat: the Framingham Heart Study.

Authors:  Elizabeth K Speliotes; Joseph M Massaro; Udo Hoffmann; Ramachandran S Vasan; James B Meigs; Dushyant V Sahani; Joel N Hirschhorn; Christopher J O'Donnell; Caroline S Fox
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

4.  Sonographic fatty liver and hepatitis B virus carrier status: synergistic effect on liver damage in Taiwanese adults.

Authors:  Yu-Cheng Lin; Shu-Tin Hsiao; Jong-Dar Chen
Journal:  World J Gastroenterol       Date:  2007-03-28       Impact factor: 5.742

5.  Wavelet-based Computationally-Efficient Computer-Aided Characterization of Liver Steatosis using Conventional B-mode Ultrasound Images.

Authors:  Manar N Amin; Muhammad A Rushdi; Raghda N Marzaban; Ayman Yosry; Kang Kim; Ahmed M Mahmoud
Journal:  Biomed Signal Process Control       Date:  2019-04-05       Impact factor: 3.880

6.  Prevalence of and risk factors for non-alcoholic fatty liver disease in a Chinese population: An 8-year follow-up study.

Authors:  Zhen-Ya Lu; Zhou Shao; Ya-Li Li; Muhuyati Wulasihan; Xin-Hua Chen
Journal:  World J Gastroenterol       Date:  2016-04-07       Impact factor: 5.742

7.  Comparative analyses of genetic risk prediction methods reveal extreme diversity of genetic predisposition to nonalcoholic fatty liver disease (NAFLD) among ethnic populations of India.

Authors:  Ankita Chatterjee; Analabha Basu; Abhijit Chowdhury; Kausik Das; Neeta Sarkar-Roy; Partha P Majumder; Priyadarshi Basu
Journal:  J Genet       Date:  2015-03       Impact factor: 1.166

8.  A small supernumerary marker chromosome resulting in mosaic partial tetrasomy 4q26-q31.21 in a foetus with multiple congenital malformations.

Authors:  Zhi-Tao Zhang; Wen-Xu Qi; Cai-Xia Liu; Shao-Wei Yin; Yan Zhao; Jesse Li-Ling; Yuan Lv
Journal:  J Genet       Date:  2019-03       Impact factor: 1.166

9.  The effect of miRNA-122 in regulating fat deposition in a cell line model.

Authors:  Yu-Qiang Nie; Jie Cao; Yong-Jian Zhou; Xia Liang; Yan-Lei Du; Yu-Jui Yvonne Wan; Yu-Yuan Li
Journal:  J Cell Biochem       Date:  2014-05       Impact factor: 4.429

Review 10.  NAFLD in Asia--as common and important as in the West.

Authors:  Geoffrey C Farrell; Vincent Wai-Sun Wong; Shiv Chitturi
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2013-03-05       Impact factor: 46.802

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.